Physiomics expands technical team
Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Dr Nathalie Dupuy has joined its technical team as a Biosimulation scientist.
Nathalie holds a PhD in Neuroinformatics from the University of Edinburgh and an MSc in Biomedical Engineering from Imperial College, London. Nathalie has also completed courses in AI related disciplines including data science, machine learning and natural language processing.
Dr Jim Millen, CEO, commented “As it expands, Physiomics continues to attract fantastic young talent. Nathalie will be a great addition to the team and help increase our capacity and capability to address our pipeline of project opportunities.”.
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.